Retiring the Needle: Which Tests Replace Liver Biopsy — and When

Key Takeaway: A large-scale prospective study has definitively confirmed which non-invasive tests perform best in metabolic dysfunction-associated steatotic liver disease (MASLD)—and for which specific clinical questions. While blood-based tests like NIS2+ show the most promise for detecting inflammatory liver disease, imaging modalities such as MRE and composite scores like Agile 3+ and Agile 4 demonstrate high accuracy in identifying advanced fibrosis and cirrhosis, offering a reliable roadmap for moving away from routine liver biopsy.

The Needle in the Liver and the Quest for a Better Way

For decades, the only way to understand the extent of damage from fatty liver disease was to pass a long needle between the ribs and extract a small, cylindrical core of tissue from the organ. While liver biopsy remains the “gold standard,” the experience is far from golden for the patient: it carries risks of pain, bleeding, and, in rare cases, serious complications^[2]. Furthermore, sampling less than one-fifty-thousandth of the organ’s total mass raises serious questions about how representative this tiny sliver is of the liver’s overall condition. Given that an estimated one in three adults worldwide is affected by this condition—formerly known as non-alcoholic fatty liver disease and now termed MASLD^[3]—the medical community has long been in a race to find accurate, painless alternatives. This is where the LITMUS Imaging Study comes in, offering the most rigorous and comprehensive comparison of these alternatives to date.

What Did the LITMUS Study Actually Do?

LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) was a prospective, multicenter study involving 357 participants from various European centers with biopsy-confirmed MASLD. Each participant underwent a battery of non-invasive tests, including serum-based biomarkers and advanced imaging techniques, in addition to the reference standard liver biopsy. Researchers then compared the diagnostic accuracy of each test against the biopsy results to answer three clinically critical questions: Does this patient have metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory form of fatty liver? Is advanced fibrosis (stage F3 or greater) present? And has the patient developed cirrhosis (stage F4)?

The results revealed a clinically meaningful and striking distinction. For detecting MASH—the active inflammatory state that drives disease progression—the serum biomarker NIS2+ performed best, achieving an area under the curve (AUC) of 0.83, though it did not significantly exceed the study’s predefined minimum acceptable performance (MAC) criterion. In identifying advanced fibrosis (≥F3), magnetic resonance elastography (MRE) led the pack with an AUC of 0.91, while the composite clinical score Agile 3+ reached 0.84; both met the MAC criterion. For diagnosing cirrhosis, the results were even more promising: MRE (AUC 0.91), liver stiffness measurement by vibration-controlled transient elastography (VCTE-LSM, AUC 0.87), Agile 3+ (AUC 0.89), and Agile 4 (AUC 0.88) all successfully surpassed the MAC value^[1].

Why Do Different Tests Excel at Different Questions?

To understand why no single test achieves absolute success in answering all clinical questions, it’s essential to grasp what is actually happening inside a liver with MASLD. The disease progresses in stages. First, triggered by insulin resistance, visceral obesity, and metabolic dysfunction, excess fat accumulates inside the hepatocytes, the liver’s workhorse cells^[4]. For many, the story ends there: simple steatosis, a fat buildup that may never progress. In a significant subset of patients, however, this fat accumulation triggers a chain of inflammation. Damaged hepatocytes release danger signals that attract immune cells to the area, further exacerbating the injury. This is the MASH stage, where the disease is inflammatory and actively destructive.

Inflammation is a biochemical event. It leaves molecular fingerprints in the blood: specific proteins, lipid metabolites, and markers of cell death. This is why serum panels like NIS2+, which assess several of these circulating signals together, are more successful at detecting MASH than imaging modalities. In contrast, MRE and VCTE measure the physical stiffness of liver tissue. These methods are excellent at measuring what they were designed to measure: the mechanical consequence of fibrosis—the progressive buildup of collagen scar tissue that replaces normal liver architecture^[5]. Early-stage inflammation doesn’t always stiffen the liver, but advanced fibrosis and cirrhosis certainly do. Years of accumulated collagen cross-links from chronic injury transform the liver from a soft, pliable organ into something with the consistency of a rubber ball.

The Agile composite scores serve as a bridge connecting these two worlds. These scores combine stiffness values from elastography with clinical variables such as age, sex, platelet count, and diabetes status to produce a single numerical value that reflects both the structural and metabolic dimensions of the disease^[6]. Their strong performance across different stages of fibrosis in the LITMUS data demonstrates that this integrated approach provides real diagnostic added value beyond blood tests or imaging alone.

Notable Limitations

No single study rewrites clinical practice overnight. The LITMUS study’s cohort of 357 participants, while well-characterized, is modest in size. The fact that all participants had biopsy-proven MASLD means the results may not be fully generalizable to unselected primary care populations, where disease prevalence is lower and spectrum bias could alter test performance. MRE, despite its impressive accuracy, remains expensive and is not universally available, especially outside of academic medical centers. Furthermore, the failure of NIS2+ to clearly exceed the minimum acceptable performance criterion for MASH detection indicates that the search for a reliable blood biomarker for MASH is not yet over.

What These Results Mean for Patients

For the millions of people living with fatty liver disease, the practical message from the LITMUS study is genuinely hopeful. If the clinical question is whether advanced fibrosis or cirrhosis has developed—the factors that most directly impact prognosis and treatment urgency—MRE, VCTE, and the Agile scores can now answer it with high confidence, sparing many patients the discomfort and risk of a biopsy. Physicians can increasingly adopt a stepwise approach: screening with widely available tools like VCTE and FIB-4 in primary care, followed by ordering an MRE or applying Agile scores when advanced disease is suspected. This study provides the evidence base, supported by real prospective data, that turns such an algorithm from a retrospective hope into a validated strategy. The era of biopsy-free diagnosis in MASLD is no longer a distant dream; it is becoming a reality, one validated biomarker at a time.

The encouraging results of this study may lead physicians to be more aggressive in treating fatty liver, a condition we see frequently in clinical practice and which is now the leading cause of cirrhosis. Specifically, it could strengthen a physician’s rationale for using weight-loss injections—namely, GLP-1 agonists—which are widely used in treating obesity and metabolic disorders. Furthermore, the findings can serve as a serious warning to patients about a potentially negative trajectory, thereby improving their adherence to treatment. The integration of the tests proposed in this study into clinical practice, along with their becoming more affordable, will mark a significant milestone in the management of fatty liver disease.

Scientific Sources

1. Pavlides M, et al. Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study. Nature medicine. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42498741/
2. Rockey DC, et al. Liver biopsy. Hepatology. 2009. DOI: 10.1002/hep.22742
3. Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. DOI: 10.1097/HEP.0000000000000520
4. Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018. DOI: 10.1038/s41591-018-0104-9
5. Venkatesh SK, et al. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013. DOI: 10.1002/jmri.23731
6. Sanyal AJ, et.al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023. DOI: 10.1016/j.jhep.2022.10.034